Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Cynthia WeigelDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. cynthia.weigel@vcuhealth.org.ORCID 0000-0003-3132-4203
Md Lokman HossenDepartment of Physics and Biomolecular Sciences Institute, Florida International University, Miami, FL, USA.ORCID 0000-0002-6059-3501
Ryan D R BrownDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.ORCID 0000-0003-2880-0301
Can E SenkalDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Christopher D GreenDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.ORCID 0000-0002-7983-7449
Jason NewtonDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Sumit SahaDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Elisa N D PalladinoDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Bin NiDepartment of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Francesco S CeliDepartment of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.ORCID 0000-0001-7218-7052
Xianjun FangDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Frank D CorwinDepartment of Radiology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Huanyu Z LiCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-5482-9936
David B SauerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9291-4640
Prem P ChapagainDepartment of Physics and Biomolecular Sciences Institute, Florida International University, Miami, FL, USA.ORCID 0000-0002-0999-4975
Sarah SpiegelDepartment of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. sarah.spiegel@vcuhealth.org.ORCID 0000-0003-0751-2634
Funding
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Renato Martins · 1985 to 2026
$51.0M
Ins and outs of the bioactive sphingolipid metabolite sphingosine-1-phosphateR35GM152058 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARAH SPIEGEL · 2024 to 2026
$1.2M
New approach for cholesterol and sphingolipid reduction in Niemann-Pick C1 diseaseR00HD096117 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEWTON, JASON CHARLES · 2020 to 2022
$662k
NCI NIH HHS P30 CA016059NICHD NIH HHS R00 HD096117NIGMS NIH HHS R35 GM152058U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM152058
6 · The paper itself
Abstract
Spinster homolog 2 (SPNS2) exports the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) out of cells to regulate processes important for health and diseases. However, the molecular mechanism underlying SPNS2 transport functions and its precise physiological roles are not fully understood. Here, through a series of complementary approaches in mice, cellular assays, and particularly with in vitro cell-free binding and transport assays, we show that SPNS2 has antiporter-like activity, transporting S1P out of cells and glucose in. We demonstrate that SPNS2 directly binds glucose and transports it and identify key amino acid residues of SPNS2 involved in glucose engagement and import. Our data reveal that S1P, which enters from the cytosolic side of SPNS2 facilitates conformational changes, enabling extracellular glucose to move inward through the central cavity. Thus, we identify a mechanism that dynamically contributes to glucose homeostasis in response to metabolic and sphingolipid cues with clinical and pathophysiological implications.
Indexed as
Anion Transport ProteinsGlucoseLysophospholipidsSphingosineAnimalsBiological TransportHEK293 CellsHumansMiceAnion Transport ProteinsGlucoseLysophospholipidsSphingosinesphingosine 1-phosphateSpns2 protein, mouse
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
SPNS2 exports sphingosine-1-phosphate and imports glucose. · full record | Socratic